Wild-card patent extensions as a means to incentivize research and development of antibiotics.
Antibiotic resistance is a serious public health problem on a global scale. In both developed and developing countries, the unpleasant consequences of the phenomenon are being felt. This paper discusses wild-card patent extensions as a means to incentivize research and development of new antibiotics. The thesis defended in the paper is that the implementation of such patent extensions is an appropriate legislative response to the problem of antibiotic resistance. The general idea of wild-card patent extensions is presented in the first part of the paper. A number of objections to the idea are thereafter discussed and rejected.
Sonderholm
Jorn
J
Department of Athletics, Georgetown University, Washington, DC, USA.
D000900:Anti-Bacterial Agents / Q000600:supply & distribution*; D003362:Cost-Benefit Analysis; D055808:Drug Discovery / Q000191:economics* / Q000941:ethics / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000941:ethics / Q000331:legislation & jurisprudence; D004352:Drug Resistance, Microbial; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D014943:Global Health; D006801:Humans; D028681:Moral Obligations; D010330:Patents as Topic / Q000941:ethics / Q000331:legislation & jurisprudence*; D012935:Social Justice
D000900:Anti-Bacterial Agents